PortfoliosLab logoPortfoliosLab logo
ACAD vs. ABT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACAD vs. ABT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and Abbott Laboratories (ABT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ACAD achieves a -15.39% return, which is significantly higher than ABT's -26.92% return. Over the past 10 years, ACAD has underperformed ABT with an annualized return of -3.24%, while ABT has yielded a comparatively higher 11.16% annualized return.


ACAD

1D
2.31%
1M
7.11%
YTD
-15.39%
6M
-18.79%
1Y
0.53%
3Y*
-2.67%
5Y*
-2.01%
10Y*
-3.24%

ABT

1D
3.07%
1M
3.57%
YTD
-26.92%
6M
-26.48%
1Y
-30.68%
3Y*
-3.82%
5Y*
-2.30%
10Y*
11.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ACAD vs. ABT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ACAD
ACADIA Pharmaceuticals Inc.
-15.39%45.56%-41.39%96.67%-31.79%-56.34%24.96%164.56%-46.30%4.40%
ABT
Abbott Laboratories
-26.92%12.87%4.81%2.26%-20.68%30.53%28.04%22.08%29.06%52.03%

Correlation

The correlation between ACAD and ABT is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.25

Correlation (3Y)
Calculated over the trailing 3-year period

0.17

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.25

Correlation (All Time)
Calculated using the full available price history since May 27, 2004

0.26

Fundamentals

Market Cap

ACAD:

$3.90B

ABT:

$158.16B

EPS

ACAD:

$2.20

ABT:

$3.59

PE Ratio

ACAD:

10.28

ABT:

25.22

PEG Ratio

ACAD:

0.06

ABT:

1.57

PS Ratio

ACAD:

3.53

ABT:

3.51

PB Ratio

ACAD:

3.13

ABT:

2.39

Total Revenue (TTM)

ACAD:

$1.10B

ABT:

$45.13B

Gross Profit (TTM)

ACAD:

$758.58M

ABT:

$25.45B

EBITDA (TTM)

ACAD:

$104.56M

ABT:

$10.80B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACAD vs. ABT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD
ACAD Risk / Return Rank: 4141
Overall Rank
ACAD Sharpe Ratio Rank: 4343
Sharpe Ratio Rank
ACAD Sortino Ratio Rank: 3838
Sortino Ratio Rank
ACAD Omega Ratio Rank: 3838
Omega Ratio Rank
ACAD Calmar Ratio Rank: 4343
Calmar Ratio Rank
ACAD Martin Ratio Rank: 4242
Martin Ratio Rank

ABT
ABT Risk / Return Rank: 55
Overall Rank
ABT Sharpe Ratio Rank: 22
Sharpe Ratio Rank
ABT Sortino Ratio Rank: 55
Sortino Ratio Rank
ABT Omega Ratio Rank: 55
Omega Ratio Rank
ABT Calmar Ratio Rank: 1212
Calmar Ratio Rank
ABT Martin Ratio Rank: 33
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. ABT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ACADABTDifference
Sharpe ratioReturn per unit of total volatility

+1.25

Sortino ratioReturn per unit of downside risk

+1.95

Omega ratioGain probability vs. loss probability

1.03

0.78

+0.25

Calmar ratioReturn relative to maximum drawdown

0.02

-0.79

+0.81

Martin ratioReturn relative to average drawdown

0.03

-1.66

+1.69

ACAD vs. ABT - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is 0.01, which is higher than the ABT Sharpe Ratio of -1.24. The chart below compares the historical Sharpe Ratios of ACAD and ABT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ACAD vs. ABT - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, which is greater than ABT's maximum drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for ACAD and ABT.


Loading charts...

Drawdown Indicators


ACADABTDifference

Max Drawdown

Largest peak-to-trough decline

-96.29%

-45.66%

-50.63%

Max Drawdown (1Y)

Largest decline over 1 year

-27.58%

-38.99%

+11.41%

Max Drawdown (3Y)

Largest decline over 3 years

-57.87%

-39.64%

-18.23%

Max Drawdown (5Y)

Largest decline over 5 years

-57.87%

-39.64%

-18.23%

Max Drawdown (10Y)

Largest decline over 10 years

-77.18%

-39.64%

-37.54%

Current Drawdown

Current decline from peak

-60.35%

-33.81%

-26.54%

Average Drawdown

Average peak-to-trough decline

-50.26%

-10.86%

-39.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.57%

18.52%

-2.95%

Volatility

ACAD vs. ABT - Volatility Comparison

ACADIA Pharmaceuticals Inc. (ACAD) and Abbott Laboratories (ABT) have volatilities of 7.65% and 7.81%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ACADABTDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.65%

7.81%

-0.16%

Volatility (6M)

Calculated over the trailing 6-month period

26.03%

19.69%

+6.34%

Volatility (1Y)

Calculated over the trailing 1-year period

36.80%

24.86%

+11.94%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

55.36%

22.15%

+33.21%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

61.89%

23.66%

+38.23%

Dividends

ACAD vs. ABT - Dividend Comparison

ACAD has not paid dividends to shareholders, while ABT's dividend yield for the trailing twelve months is around 2.70%.


PositionTTM20252024202320222021202020192018201720162015
ABT
Abbott Laboratories
2.70%1.88%1.95%1.85%1.71%1.28%1.32%1.47%1.55%1.86%2.71%2.14%
ACAD
ACADIA Pharmaceuticals Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ACAD vs. ABT - Financials Comparison

This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B20222023202420252026
268.06M
11.16B
(ACAD) Total Revenue
(ABT) Total Revenue
Values in USD except per share items

ACAD vs. ABT - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and Abbott Laboratories over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
56.3%
Portfolio components
ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.

ABT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a gross profit of 6.28B and revenue of 11.16B. Therefore, the gross margin over that period was 56.3%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.

ABT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported an operating income of 1.84B and revenue of 11.16B, resulting in an operating margin of 16.5%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.

ABT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a net income of 1.08B and revenue of 11.16B, resulting in a net margin of 9.7%.


Frequently Asked Questions


ACAD and ABT have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ABT has higher volatility (7.81%) compared to ACAD (7.65%). In terms of maximum drawdown, ACAD dropped -96.29% vs ABT's -45.66%.

ACAD currently has the higher Sharpe Ratio (0.01 vs -1.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ACAD and ABT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer